Annexon, Inc.

$125m committed across 1 active facility, next covenant test Sep 30, 2026. ANNX

Pharmaceutical Preparations

Recent changes

  1. Jul 30, 2026Annexon, Inc. signs $125m LOAN AND SECURITY AGREEMENTSEC ↗
Tested quarterlyHeadroom not yet measuredn/a

Springing: Tested beginning on the first Revenue Testing Date after the earlier of the Third Draw Period Commencement Event or the Fourth Draw Period Commencement Event; not required if Market Capitalization ≥ $700,000,000 or Qualified Cash ≥ outstanding Term Loans.

If the initial Revenue Testing Date has occurred, Borrower shall achieve Minimum Required Net Product Revenue (determined in accordance with GAAP), measured on a trailing six (6) month basis.
Read the filing on sec.gov ↗
Tested springingHeadroom not yet measuredn/a

Springing: Beginning with the earlier of the Cash Covenant Commencement Date or the Cash Covenant Springing Date, and thereafter at all times.

not less than the product of (i) the Cash Covenant Applicable Percentage multiplied by (ii) the aggregate principal amount of the Term Loans then outstanding.
Read the filing on sec.gov ↗

Download CSV · Download JSON

LOAN AND SECURITY AGREEMENT

Signed Jul 30, 2026

Committed
$125m
Matures
n/a
TrancheSizeMaturesMargin
Term A Loan$50mn/an/a
Term B Loan$25mn/an/a
Term C Loann/an/an/a
Term D Loan$50mn/an/a
Term E Loann/an/an/a

Lenders: OXFORD FINANCE LLC, OXFORD FINANCE CREDIT FUND IV LP

No amendments on file yet.

Report an error